Opinion
Video
Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.
- Provide an overview of the current landscape of induction therapies for MCL. What role do BTK inhibitors have in this landscape?
- Aggressive induction therapy
